CLINICAL TRIALS PROFILE FOR GERMA-MEDICA MG
✉ Email this page to a colleague
All Clinical Trials for GERMA-MEDICA MG
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00270829 ↗ | Renal Effects of Intrarenal Nesiritide | Terminated | University of Maryland | Phase 4 | 2005-12-01 | The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF. |
| NCT00270829 ↗ | Renal Effects of Intrarenal Nesiritide | Terminated | University of Maryland, Baltimore | Phase 4 | 2005-12-01 | The impact of nesiritide in CHF is unclear, but it is possible that systemic vasodilation leads to adverse consequences even if the direct renal effects are positive. Therefore, this study will look at the effects of direct intrarenal administration of nesiritide on GFR and RPF. |
| NCT01033630 ↗ | Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen | Completed | Chinese University of Hong Kong | Phase 2 | 2006-01-01 | Atherosclerosis (in particular stroke and heart attack) is the most important health issue in modernized society and high blood pressure is an important predisposing factor. Hypertensive subjects with other chronic disease such as diabetes mellitus or impaired renal function are particularly vulnerable to these atherosclerotic complications in spite of standard antihypertensive therapies. Danshen and Gegen are commonly used in Chinese materia medica as treatment for cardiac symptoms and atherosclerosis-related disorders. The objective of this study is to test Danshen and Gegen as an cardiovascular-protective adjunctive regimen to prevent high-risk hypertensive cohort from primary atherosclerosis. |
| NCT01677247 ↗ | Bioequivalence Study of 4 mg Glimepiride Tablet | Completed | Dexa Medica Group | N/A | 2011-02-01 | This was a randomized, single blind, two-period, two sequence cross-over study under fasting condition to compare the bioavailability of two glimepiride 4 mg tablet formulations (test and reference formulations). |
| NCT01682577 ↗ | Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition | Completed | Dexa Medica Group | N/A | 2008-09-01 | The objective of this study was to find out whether the bioavailability of PT Dexa Medica's formulation of 4 mg perindopril tert-butylamine tablets was equivalent to that of the innovator's product (Prexum® 4 mg, Servier). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GERMA-MEDICA MG
Condition Name
Clinical Trial Locations for GERMA-MEDICA MG
Trials by Country
Clinical Trial Progress for GERMA-MEDICA MG
Clinical Trial Phase
Clinical Trial Sponsors for GERMA-MEDICA MG
Sponsor Name
